𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Promoters influence the kinetics of transgene expression following adenovector gene delivery

✍ Scribed by Ping Chen; Jie Tian; Imre Kovesdi; Joseph T. Bruder


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
299 KB
Volume
10
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

The kinetics of gene expression from adenovirus‐based delivery vectors will be an important variable influencing the efficacy and toxicity of these vectors. As different promoters have variable strengths and kinetic profiles, the optimal dose of a therapeutic transgene product over time may be achieved by varying the promoter.

Methods

We analyzed several viral and cellular promoters in the context of adenovector gene delivery in the mouse. The kinetics of transgene expression was evaluated following intramuscular and intravenous delivery.

Results

Transgene expression from the cytomegalovirus (CMV) promoter was rapidly down‐regulated in the tissues following intravenous administration of adenovectors. In contrast, transgene expression from the Rous sarcoma virus (RSV) promoter increased over time such that, at 3 weeks, expression was 10‐fold higher than that from the CMV promoter‐containing vector in all tissues. The kinetics of transgene expression from these vectors was similar when they were delivered via the intramuscular route in BALB/c, C57BL/6 and immunodeficient mice. Efficient repeat administration of an adenovirus vector, in the presence of neutralizing antibodies, was achieved in the skeletal muscle and transgene expression persisted with the same kinetics as in na__ï__ve animals.

Conclusions

These results demonstrate that the in vivo kinetics of transgene expression by adenovectors is greatly influenced by the promoter. Adenovectors can be designed to deliver a transient bolus or a sustained level of protein expression in the target tissue depending on the requirements for particular indications. These results have implications for both therapeutic and vaccine indications. Copyright © 2007 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Transcriptional silencing is associated
✍ Alan R. Brooks; Richard N. Harkins; Peiyin Wang; Hu Sheng Qian; Pengxuan Liu; Ga 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Abstract ## Background Although the transient nature of transgene expression using first‐generation adenovirus (Ad) vectors is well known, the exact mechanisms responsible for this phenomenon are uncertain. ## Methods Rats were given intramuscular (i.m.) injections of a first‐generation Ad co

The kinetics of p53-binding and histone
✍ Roberta Magrini; Debora Russo; Gilberto Fronza; Alberto Inga; Paola Menichini 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB

## Abstract We have addressed the correlation between sequence‐specific DNA binding by the tumor suppressor p53 and transactivation of various target genes, in the context of UV irradiation responses. In A549 cells (p53WT), p53 occupancy at the __p21__, __mdm2__, and __puma__ promoters increased si

The functional −443T/C osteopontin promo
✍ Julia Schultz; Peter Lorenz; Saleh M. Ibrahim; Günther Kundt; Gerd Gross; Manfre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB

## Abstract In the present report, the possible role of a recently described functional polymorphism of the osteopontin (OPN) promoter at position −443 (−443T/C) for OPN expression in melanoma cells was addressed. As shown by __real‐time__ PCR analysis, melanoma metastases that were homozygous for

Human growth hormone 1 (GH1) gene expres
✍ Martin Horan; David S. Millar; Jürgen Hedderich; Geraint Lewis; Vicky Newsway; N 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 1 views

The proximal promoter region of the human pituitary expressed growth hormone (GH1) gene is highly polymorphic, containing at least 15 single nucleotide polymorphisms (SNPs). This variation is manifest in 40 different haplotypes, the high diversity being explicable in terms of gene conversion, recurr

Retinal cell type expression specificity
✍ Alexis-Pierre Bemelmans; Sébastien Bonnel; Leïla Houhou; Noëlle Dufour; Emeline 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB

Background Gene therapy, and particularly gene restoration, is currently a great hope for non-curable hereditary retinal degeneration. Clinical applications require a gene transfer vector capable of accurately targeting particular cell types in the retina. To develop such a vector, we compared the e